Exponent, Inc. Third Quarter of Fiscal Year 2026 Financial Results Conference Call - EXPONENT INC

Explicit Guidance:

• FY2026 Net Revenue: Raised to growth of 10%–11% (previously lower).
• FY2026 EBITDA Margin: Raised to 28.0%–28.3% of net revenues (vs. 27.6% in 2025).
• Q4 2026 Net Revenue: Expected growth of 8%–10% year-over-year.
• Q4 2026 EBITDA Margin: Expected to be 26.3%–26.8% of net revenues.
• Full-Year 2026 Utilization: Expected range of 73.5%–74.0% (vs. 72.5% in 2025); Q4 specific range 69%–70%.
• Full-Year 2026 Realized Rate Increase: Expected 3.7%–4.0% year-over-year; Q4 specific expected increase 3%–3.5%.
• Full-Year 2026 Headcount: Technical FTE growth expected 4.7%–5.0% year-over-year; Q4 growth expected 4%–5%.
• FY2026 Stock-Based Compensation: Expected total of $28.1 million–$28.4 million (Q4: $5.7 million–$5.9 million).
• FY2026 Other Operating Expenses: Expected total of $53.0 million–$53.5 million (Q4: $13.5 million–$14.0 million).
• FY2026 G&A Expenses: Expected total of $28.1 million–$28.6 million (Q4: $7.2 million–$7.7 million).
• FY2026 Tax Rate: Expected 28.5% for the full year (vs. 28% in 2025); Q4 2026 expected at 28% (vs. 27.4% in Q4 2025).
• FY2026 Capital Expenditures: Expected range of $10 million–$12 million.
• Share Count: No new buyback guidance; $50 million remaining in Board authorization; no additional tax benefits anticipated from share-based awards for the remainder of 2026.

Business-Segment Outlook:

• Engineering & Scientific (85% of net revenues): Growth driven by "user research" spanning health applications, dynamic real-world environments, and sensory perception, plus dispute-related services in chemicals, consumer products, and advanced transportation.
• Environmental & Health (15% of net revenues): Growth currently at 3%; future acceleration contingent on ramping senior-level hires to expand capabilities in emerging chemicals (e.g., PFAS) and regulatory work.
• Growth Drivers: "Proactive" business grew in the "high teens" while "reactive" (disputes/failure analysis) grew in the "high single digits" on top of a strong prior-year quarter; reactive work expected to be diversified across industries rather than reliant on single large projects.

Market and Competitive Outlook:

• AI Integration: Management estimates AI is a direct element of 15%–20% of current business; expects "accelerated growth" as AI moves from hypothetical scenarios to real-world product failures and safety disputes.
• Market Structure: Demand driven by the convergence of technology, infrastructure, and humans; clients increasingly require "explainability, clarity, and trust" when intelligent products behave unexpectedly.
• Segment Specific Trends:
  • Transportation: Increased failure analysis on Advanced Driver Assistance Systems (ADAS) and autonomous vehicles, with product liability suits and regulatory investigations already active (e.g., San Francisco vehicle incidents).
  • Consumer Electronics/Health: Shift toward evaluating wearables and sensors in uncontrolled real-world environments (e.g., predicting cardiovascular health), raising questions about the trustworthiness of AI-driven predictions.
  • Infrastructure/Data Centers: Work expanding to cover supply chain reliability, thermal management, liquid cooling failures, and construction disputes related to AI systems.
  • Medical Devices: Anticipated ramp-up in reactive work regarding AI-driven health decisions from wearable technology.

Macro / Industry Outlook:

• Economic/Industry Cycle: Management views demand drivers as "strengthening" and not short-term; no expected slowing in demand despite easier year-over-year comparisons in Q4.
• Regulatory/Societal: Rising expectations for safety, reliability, and performance from consumers and regulators are creating "harder" questions for clients, directly benefiting the company's independent analysis model.
• Seasonality: Q4 utilization is seasonally lower (69%–70%) due to holidays/vacations but expected to reflect robust activity levels comparable to Q3 (77% adjusted).

Strategic Initiatives:

• Talent Acquisition: Aggressive "turned up" recruiting dials for FY2027; prioritizing Human Factors, Biomechanics, Thermal Scientists, Polymer/Metallurgists, and Senior Principal-level hires in Health & Environmental to seed future growth.
• Capability Expansion: Hiring from competitors, regulators, and academia to build teams for emerging chemical regulations (PFAS replacements) and complex human-machine interface challenges.
• Capital Allocation: Continuing dividend payments and buybacks only when stock price pullbacks occur; $50 million authorization remaining; evaluating small M&A opportunities and internal business investments.

Risks and Headwinds to Outlook:

• Reactive Work Lag: While AI-related disputes are emerging, the full litigation/regulatory "percolation" into the judicial system may take time (historical analogy to EV battery recalls).
• Project Mix Volatility: Single large projects (e.g., the 4% revenue project from Q2) can create variance; such projects are expected to wind down to under 1% of revenue in Q4.
• Cost Management: Increases in compensation expense (driven by hiring/retention) and operating expenses (corporate infrastructure, travel/G&A) could pressure margins if revenue growth does not keep pace.
• Seasonality: Q4 revenue growth guidance (8%–10%) is lower than Q3 (18%) primarily due to a tougher prior-year comparable and seasonal utilization drops, not necessarily a demand slowdown.

Management Tone on the Future:

• Confidence Level: High; management expresses strong confidence in the "long-term growth framework" and the ability to deliver "sustainable, long-term value."
• Differentiation: Emphasis on being "built for hard questions" and possessing an "integrated ecosystem" of 1,000+ consultants (700+ PhDs) to solve complex, high-consequence challenges.
• Momentum: Stated they are "well positioned to finish 2026 on a strong note" with momentum carrying into the fourth quarter.

Miscellaneous:

• Share Repurchases: $171 million utilized over the past 12 months, reducing shares by 5% (from 51.2M to 48.4M average diluted shares); no repurchases occurred in Q3 2025.
• Deferred Compensation: Q3 2026 saw a $159,000 gain (vs. $7 million in Q3 2025); these gains/losses are offset in miscellaneous income and do not impact the bottom line.